UNLABELLED: Liver fibrosis is a wound healing response to chronic liver injury and inflammation in which macrophages and infiltrating monocytes participate in both the development and resolution phase. In humans, three monocyte subsets have been identified: the classical CD14++CD16-, intermediate CD14++CD16+, and nonclassical CD14+CD16++ monocytes. We studied the phenotype and function of these monocyte subsets in peripheral blood and liver tissue from patients with chronic inflammatory and fibrotic liver diseases. The frequency of intrahepatic monocytes increased in disease compared with control liver tissue, and in both nondiseased and diseased livers there was a higher frequency of CD14++CD16+ cells with blood. Our data suggest two nonexclusive mechanisms of CD14++CD16+ accumulation in the inflamed liver: (1) recruitment from blood, because more than twice as many CD14++CD16+ monocytes underwent transendothelial migration through hepatic endothelial cells compared with CD14++CD16- cells; and (2) local differentiation from CD14++CD16- classical monocytes in response to transforming growth factor β and interleukin (IL)-10. Intrahepatic CD14++CD16+ cells expressed both macrophage and dendritic cell markers but showed high levels of phagocytic activity, antigen presentation, and T cell proliferation and secreted proinflammatory (tumor necrosis factor α, IL-6, IL-8, IL-1β) and profibrogenic cytokines (IL-13), chemokines (CCL1, CCL2, CCL3, CCL5), and growth factors (granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor), consistent with a role in the wound healing response. CONCLUSION: Intermediate CD14++CD16+ monocytes preferentially accumulate in chronically inflamed human liver as a consequence of enhanced recruitment from blood and local differentiation from classical CD14++CD16- monocytes. Their phagocytic potential and ability to secrete inflammatory and profibrogenic cytokines suggests they play an important role in hepatic fibrogenesis.
UNLABELLED: Liver fibrosis is a wound healing response to chronic liver injury and inflammation in which macrophages and infiltrating monocytes participate in both the development and resolution phase. In humans, three monocyte subsets have been identified: the classical CD14++CD16-, intermediate CD14++CD16+, and nonclassical CD14+CD16++ monocytes. We studied the phenotype and function of these monocyte subsets in peripheral blood and liver tissue from patients with chronic inflammatory and fibrotic liver diseases. The frequency of intrahepatic monocytes increased in disease compared with control liver tissue, and in both nondiseased and diseased livers there was a higher frequency of CD14++CD16+ cells with blood. Our data suggest two nonexclusive mechanisms of CD14++CD16+ accumulation in the inflamed liver: (1) recruitment from blood, because more than twice as many CD14++CD16+ monocytes underwent transendothelial migration through hepatic endothelial cells compared with CD14++CD16- cells; and (2) local differentiation from CD14++CD16- classical monocytes in response to transforming growth factor β and interleukin (IL)-10. Intrahepatic CD14++CD16+ cells expressed both macrophage and dendritic cell markers but showed high levels of phagocytic activity, antigen presentation, and T cell proliferation and secreted proinflammatory (tumor necrosis factor α, IL-6, IL-8, IL-1β) and profibrogenic cytokines (IL-13), chemokines (CCL1, CCL2, CCL3, CCL5), and growth factors (granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor), consistent with a role in the wound healing response. CONCLUSION: Intermediate CD14++CD16+ monocytes preferentially accumulate in chronically inflamed human liver as a consequence of enhanced recruitment from blood and local differentiation from classical CD14++CD16- monocytes. Their phagocytic potential and ability to secrete inflammatory and profibrogenic cytokines suggests they play an important role in hepatic fibrogenesis.
Authors: Jeremy S Duffield; Stuart J Forbes; Christothea M Constandinou; Spike Clay; Marina Partolina; Srilatha Vuthoori; Shengji Wu; Richard Lang; John P Iredale Journal: J Clin Invest Date: 2005-01 Impact factor: 14.808
Authors: F Marra; R DeFranco; C Grappone; S Milani; S Pastacaldi; M Pinzani; R G Romanelli; G Laffi; P Gentilini Journal: Am J Pathol Date: 1998-02 Impact factor: 4.307
Authors: Evaggelia Liaskou; Marika Karikoski; Gary M Reynolds; Patricia F Lalor; Chris J Weston; Nick Pullen; Marko Salmi; Sirpa Jalkanen; David H Adams Journal: Hepatology Date: 2011-01-10 Impact factor: 17.425
Authors: Ekihiro Seki; Samuele De Minicis; Geum-Youn Gwak; Johannes Kluwe; Sayaka Inokuchi; Christina A Bursill; Josep M Llovet; David A Brenner; Robert F Schwabe Journal: J Clin Invest Date: 2009-07 Impact factor: 14.808
Authors: Rifaat Safadi; Masayuki Ohta; Carlos E Alvarez; M Isabel Fiel; Meena Bansal; Wajahat Z Mehal; Scott L Friedman Journal: Gastroenterology Date: 2004-09 Impact factor: 22.682
Authors: Jill E Kolodsick; Galen B Toews; Claudia Jakubzick; Cory Hogaboam; Thomas A Moore; Andrew McKenzie; Carol A Wilke; Cara J Chrisman; Bethany B Moore Journal: J Immunol Date: 2004-04-01 Impact factor: 5.422
Authors: Patricia F Lalor; Phoebe Jun Sun; Chris J Weston; Azucena Martin-Santos; Michael J O Wakelam; David H Adams Journal: Hepatology Date: 2007-02 Impact factor: 17.425
Authors: Kristofer T Michalson; Andrew N Macintyre; Gregory D Sempowski; J Daniel Bourland; Timothy D Howard; Gregory A Hawkins; Gregory O Dugan; J Mark Cline; Thomas C Register Journal: Radiat Res Date: 2019-06-04 Impact factor: 2.841
Authors: Joel T Haas; Luisa Vonghia; Denis A Mogilenko; An Verrijken; Olivier Molendi-Coste; Sébastien Fleury; Audrey Deprince; Artemii Nikitin; Eloïse Woitrain; Lucie Ducrocq-Geoffroy; Samuel Pic; Bruno Derudas; Hélène Dehondt; Céline Gheeraert; Luc Van Gaal; Ann Driessen; Philippe Lefebvre; Bart Staels; Sven Francque; David Dombrowicz Journal: Nat Metab Date: 2019-06-14
Authors: Bradley H Collins; Zoie E Holzknecht; Kellie A Lynn; Gregory D Sempowski; Catherine C Smith; Songling Liu; William Parker; Don C Rockey Journal: Liver Int Date: 2013-05-26 Impact factor: 5.828
Authors: Adam S Arterbery; Awo Osafo-Addo; Yaron Avitzur; Maria Ciarleglio; Yanhong Deng; Steven J Lobritto; Mercedes Martinez; David A Hafler; Markus Kleinewietfeld; Udeme D Ekong Journal: J Immunol Date: 2016-04-18 Impact factor: 5.422